Europe

The giant asset manager's Private Equity Solutions platform will make about 20-25 investments in a mix of early-stage funds and co-investments in later-stage companies.

Venture funds raised $41.6bn worldwide in the first half of this year, down from $60bn in H1 of last year, according to exclusive research by Venture Capital Journal.

'We decided to actively go find partners in Canada and Europe to be long-term partners,' managing partner John Tough tells Venture Capital Journal.

Mat Powley, a partner on the private capital team, talks about the $28bn UK multifamily office’s approach to new and venture GPs for its flagship fund of funds.

LPs include French corporates Groupe ADP and Valeo, and Spanish government investment organization Institut Català de Finances, PEI reported.

The fund’s strategic and impact-oriented LPs include big pharma names such as Pfizer, Bristol Myers Squibb, AARP and Alzheimer’s Research UK, which are excited by improved scientific understanding of dementia that promise to increase clinical trial successes.

The fund, which is targeting €125m, will focus on early-stage start-ups across Europe operating in sectors such as cybersecurity, information superiority, robotics, AI, autonomous systems and space technology.

The new fund, which is 25% larger than its debut, is backed by Isomer Capital, Exor NV's Lingotto, Fondazione Compagnia di San Paolo, Grinnell College's Endowment, RSJ Investments and Aldea Ventures, Lunar says.

Leyla Holterud 'is the ideal leader to scale our European platform and the bridges we have been building between Europe and the rest of the world for well over a decade,' says Vintage co–managing partner Asaf Horesh.